This is unexpected as one might predict that reduced levels of p16 would result in deregulated activation of cyclin-dependent kinase 4/6 resulting in uncontrolled cell-cycle transition through the Rb pathway, leading to a higher tumour growth rate. The gene discussed is RB1; the disease is neoplasm.